Y Intercept Hong Kong Ltd Makes New $1.01 Million Investment in Glaukos Co. (NYSE:GKOS)

Y Intercept Hong Kong Ltd acquired a new stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 7,724 shares of the medical instruments supplier's stock, valued at approximately $1,006,000.

Several other large investors also recently modified their holdings of GKOS. Wellington Management Group LLP grew its stake in Glaukos by 294.5% in the third quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier's stock valued at $284,501,000 after purchasing an additional 1,630,270 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Glaukos in the 2nd quarter valued at about $67,460,000. Primecap Management Co. CA lifted its position in Glaukos by 43.9% during the second quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier's stock worth $144,483,000 after acquiring an additional 372,180 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Glaukos by 148.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier's stock worth $48,805,000 after acquiring an additional 246,322 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Glaukos by 47.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier's stock worth $83,609,000 after purchasing an additional 207,338 shares during the period. 99.04% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Glaukos

In other news, COO Joseph E. Gilliam sold 2,275 shares of the business's stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at $14,198,425.93. The trade was a 2.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.40% of the company's stock.

Glaukos Price Performance

Shares of NYSE GKOS traded down $1.50 during mid-day trading on Friday, hitting $138.82. 609,996 shares of the stock traded hands, compared to its average volume of 569,477. Glaukos Co. has a twelve month low of $65.00 and a twelve month high of $147.65. The firm has a 50 day simple moving average of $136.10 and a two-hundred day simple moving average of $126.60. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. During the same quarter last year, the business earned ($0.50) EPS. The firm's quarterly revenue was up 23.9% on a year-over-year basis. Research analysts anticipate that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Stephens raised Glaukos to a "strong-buy" rating in a report on Monday, December 2nd. Morgan Stanley cut shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price objective for the company. in a research note on Monday, December 2nd. BTIG Research increased their target price on shares of Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Truist Financial lifted their price target on shares of Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Finally, Stifel Nicolaus raised their price objective on Glaukos from $145.00 to $153.00 and gave the stock a "buy" rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $143.17.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.